Scott Reule

Dr. Scott Reule

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2024 in Kidney360
Verified
Journal Article
Open access
DMDaniel P. Murphy
Daniel P. Murphy
JWJulian Wolfson
Julian Wolfson
SRScott Reule
Scott Reule
KJKirsten L. Johansen
Kirsten L. Johansen
AIAreef Ishani
Areef Ishani
PDPaul E. Drawz
Paul E. Drawz
Key Points: Post-AKI sodium–glucose cotransporter-2 inhibitor use was associated with a reduced risk for progression of CKD and for recurrent AKI among veterans with diabetic kidney disease even after accounting for recovery from the index AKI. A minority of Veterans with diabetic kidney disease received a sodium–glucose cotransporter-2 inhibitor after having had AKI during the study period. Background: The effect of sodium–glucose cotransporter-2 inhibitor (SGLT2i) on kidney function after AKI is unknown. Methods: The study population was drawn from a retrospective cohort of Veterans with diabetes mellitus type 2 (DM2) and proteinuria. The study exposure was time-varying use of SGLT2i after an index AKI hospitalization. The two study outcomes were time to (1) a sustained decrease in eGFR over at least 3 months to <60 ml/min per 1.73 m2 and ≥30% below a post-AKI–updated eGFR and (2) recurrent hospitalization with AKI. AKI was defined as a rise in serum creatinine concentration to ≥50% above a moving outpatient creatinine baseline. DM2 was defined by ≥2 billing codes related to DM2 before the index AKI; proteinuria was defined by the most recent albuminuria, proteinuria, or urinalysis test. Veterans were required to have a baseline eGFR and an eGFR 3–12 months after the index AKI hospitalization ≥30 ml/min per 1.73 m2. Results: Ten thousand thirty-six Veterans met study inclusion criteria. Two thousand seven hundred and ninety-four (28%) received a SGLT2i. Seven hundred and seventy-five (8%) had CKD progression, and 1816 (18%) had recurrent AKI over a median follow-up of 1.8 and 1.7 years, respectively, which began 1 year after the index AKI hospitalization. SGLT2i use was associated with lower risk for CKD progression (adjusted hazard ratio 0.72 [95% confidence interval, 0.57 to 0.91]) and for recurrent AKI (adjusted hazard ratio 0.75 [95% confidence interval, 0.65 to 0.88]). Conclusions: SGLT2i use was associated with a lower risk for CKD progression and for recurrent AKI among those with diabetic kidney disease and recent AKI.

7 August 2023 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
DMDaniel P. Murphy
Daniel P. Murphy
JWJulian Wolfson
Julian Wolfson
SRScott Reule
Scott Reule
KJKirsten L. Johansen
Kirsten L. Johansen
AIAreef Ishani
Areef Ishani
PDPaul E. Drawz
Paul E. Drawz
Significance Statement: Among patients with CKD, optimal use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers after AKI is uncertain. Despite these medications' ability to reduce risk of mortality and other adverse outcomes, there is concern that ACEi/ARB use may delay recovery of kidney function or precipitate recurrent AKI. Prior studies have provided conflicting data regarding the optimal timing of these medications after AKI and have not addressed the role of kidney recovery in determining appropriate timing. This study in US Veterans with diabetes mellitus and proteinuria demonstrated an association between ACEi/ARB use and lower mortality. This association was more pronounced with earlier post-AKI ACEi/ARB use and was not meaningfully affected by initiating ACEis/ARBs before versus after recovery from AKI. Background: Optimal use of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) after AKI is uncertain. Methods: Using data derived from electronic medical records, we sought to estimate the association between ACEi/ARB use after AKI and mortality in US military Veterans with indications for such treatment (diabetes and proteinuria) while accounting for AKI recovery. We used ACEi/ARB treatment after hospitalization with AKI (defined as serum creatinine ≥50% above baseline concentration) as a time-varying exposure in Cox models. The outcome was all-cause mortality. Recovery was defined as return to ≤110% of baseline creatinine. A secondary analysis focused on ACEi/ARB use relative to AKI recovery (before versus after). Results: Among 54,735 Veterans with AKI, 31,146 deaths occurred over a median follow-up period of 2.3 years. Approximately 57% received an ACEi/ARB <3 months after hospitalization. In multivariate analysis with time-varying recovery, post-AKI ACEi/ARB use was associated with lower risk of mortality (adjusted hazard ratio [aHR], 0.74; 95% confidence interval [CI], 0.72 to 0.77). The association between ACEi/ARB use and mortality varied over time, with lower mortality risk associated with earlier initiation (P for interaction with time <0.001). In secondary analysis, compared with those with neither recovery nor ACEi/ARB use, risk of mortality was lower in those with recovery without ACEi/ARB use (aHR, 0.90; 95% CI, 0.87 to 0.94), those without recovery with ACEi/ARB use (aHR, 0.69; 95% CI, 0.66 to 0.72), and those with ACEi/ARB use after recovery (aHR, 0.70; 95% CI, 0.67 to 0.73). Conclusions: This study demonstrated lower mortality associated with ACEi/ARB use in Veterans with diabetes, proteinuria, and AKI, regardless of recovery. Results favored earlier ACEi/ARB initiation.

1 April 2011 in Organogenesis
Verified
Journal Article
Open access
PDF file
SRScott Reule
Scott Reule
SGSandeep Gupta
Sandeep Gupta
Given its complexity, high metabolic activity and excretory functions, the kidney is particularly susceptible to acute ischemic and toxin-mediated injury. Current therapies do not facilitate kidney regeneration, and there is an increasing interest in newer therapies that are based on cellular sources of kidney regeneration, such as stem cell therapy. Our understanding of cellular sources for kidney regeneration and stem cells present in the adult kidney has dramatically evolved over the recent years. Herein, we discuss the current understanding of kidney stem cells present in the adult mammalian kidney and their role in kidney regeneration. We have also summarized the best available evidence supporting the role of stem cells in kidney regeneration.

8 May 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
ASAshutosh M. Shukla
Ashutosh M. Shukla
KCKerri L Cavanaugh
Kerri L Cavanaugh
HJHuanguang Jia
Huanguang Jia
JHJennifer Hale-Gallardo
Jennifer Hale-Gallardo
AWAnuradha Wadhwa
Anuradha Wadhwa
SCSusan T. Crowley
Susan T. Crowley
Kidney health advocacy organizations and leaders in the nephrology community have repeatedly emphasized the need to increase home dialysis utilization in the United States. Limited awareness and understanding of options for the management of kidney failure among patients living with advanced CKD is a significant barrier to increasing the selection and use of home dialysis. Studies have shown that providing targeted comprehensive patient education before the onset of kidney failure can improve patients' awareness of kidney disease and substantially increase the informed utilization of home dialysis. Unfortunately, in the absence of validated evidence-based education protocols, outcomes associated with home dialysis use vary widely among published studies, potentially affecting the routine implementation and reporting of these services among patients with advanced CKD. This review provides pragmatic guidance on establishing effective patient-centered education programs to empower patients to make informed decisions about their KRT and, in turn, increase home dialysis use.

15 September 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
AWAnuradha Wadhwa
Anuradha Wadhwa
SRScott Reule
Scott Reule
KCKerri L Cavanaugh
Kerri L Cavanaugh
MFMichael J. Fischer
Michael J. Fischer
KMKaren Mackichan
Karen Mackichan
ASAshutosh M. Shukla
Ashutosh M. Shukla
Peritoneal dialysis (PD) use among the US Veteran population is lower than in the non-Veteran kidney failure population. Enhancing access to PD within the Veteran Health Administration (VHA) may be crucial for achieving the Advancing American Kidney Health Executive Order goals. The VHA Home Dialysis Committee conducted a nationwide survey of nephrology stakeholders to assess Veterans' access to PD across the VHA and identify barriers and opportunities for the growth of VHA-affiliated PD services. Participants were invited through email and completed an electronic questionnaire consisting of 17 PD access items and 15 respondent characteristic items. Of the 141 eligible centers, 117 (83%) responded, including 97 facilities that provide nephrology services. Respondents indicated that PD could ideally serve 25% (interquartile range, 15%–40%) of Veterans with kidney failure. Most (62%) of the nephrology service-providing centers offered outpatient hemodialysis; however, only 28% reported providing outpatient PD services, with a median census of 10 Veterans. Among those lacking, 30% expressed a desire to establish outpatient PD services. The availability of comprehensive KRT-directed prekidney failure education, an inpatient PD program, or respondents' perceptions of Veteran interest in PD were positively associated ( P < 0.05) with their desire to establish outpatient PD services. System-related challenges, such as limited space and capital costs of establishing a program, alongside staff-related issues such as insufficient availability of trained nurses and support staff, were frequently cited barriers to PD programs. Respondents commonly cited the need for formal VHA-specific policies and procedural standards, administrative guides to establish local PD and patient education programs, and VHA-based PD nurse training assistance as strategies to address PD underutilization. Our findings suggest that the Veterans' lack of access to VHA-based PD programs may be an underrecognized barrier to their PD utilization. VHA nephrology stakeholders have a high desire to establish PD services but require local and system-based support to address PD underuse across the VHA.

26 August 2019 in Journal of Renal Care
Verified
Journal Article
Closed access
PDF file
DHDamian Hall
Damian Hall
DSDaniel Shaughnessy
Daniel Shaughnessy
PDPaul Drawz
Paul Drawz
SASunil Akkina
Sunil Akkina
AEAndrew Esten
Andrew Esten
SRScott Reule
Scott Reule